After 25 hours, goldfish that had received salt treatment had far less mucus weight. After 25 hours, goldfish given polyvinylpyrrolidone (PVP) had a noticeably higher mucus weight. Mucus weight in koi carp treated with polyvinylpyrrolidone (PVP) and salt was significantly reduced at 1 and 25 hours. After 25 hours, the control koi's mucous was noticeably greater. The three koi treated with polyvinylpyrrolidone (PVP) and salt were found to have healed more fully and remained healthier than the other treated fish and the control group after two weeks [1].

Absorption, Distribution and Excretion
This study investigated the in vivo distribution of N-[14C]-vinyl-2-pyrrolidone following a single intravenous injection in male Sprague-Dawley rats. …The highest tissue concentrations of radioactive substances were observed in the liver and small intestine within 6 hours of administration. At this time, approximately 19% of the dose was excreted via bile; however, by 12 hours, only about 0.4% was excreted via feces, while approximately 75% was excreted via urine. Thus, a significant enterohepatic circulation of bile metabolites appears to exist. Very small amounts of the administered substance were excreted unchanged. In one rat, 12% of the urinary radioactivity was present as acetic acid. No other metabolites were identified. Following oral administration, 1-vinyl-2-pyrrolidone was primarily distributed in the liver and small intestine. A portion was excreted in the urine as acetate, but the majority (88%) was bound to water-soluble acidic compounds. Following intravenous administration, the half-life of 14C-1-vinyl-2-pyrrolidone cleared from the bloodstream was approximately 2 hours. Unmetabolized 1-vinyl-2-pyrrolidone accounted for <0.6% of the administered dose. In vivo distribution of N-[14C-vinyl]-2-pyrrolidone following a single intravenous injection was investigated in male Sprague-Dawley rats. Plasma concentrations of the intact compound decreased rapidly within 6 hours after administration… 74.9% of the 5 microcurie dose was excreted in urine within 12 hours, compared to 18.7% in bile within 6 hours. The 14C activity attributable to the intact compound in urine was less than 0.59% of the dose, and in bile less than 0.46%. Tissue distribution studies showed the highest accumulation of 14C activity in the liver and small intestine and their contents within 6 hours after administration of N-[14C-vinyl]-2-pyrrolidone. Urinary analysis for metabolite identification showed that 12% of the radioactive dose was incorporated into acetate, with the remainder largely present as water-soluble acidic compounds. The toxic effects of vinylpyrrolidone and/or vinyl acetate (VP-VA) were investigated in rats. Female Wistar rats were anesthetized with ether and administered 0.5 mL of a standard VP-VA solution (10 g VP-VA dissolved in 15 mL of physiological saline) intratracheally. Other rats were subcutaneously injected daily with up to seven times the standard dose (2 mL), at doses ranging from 1.1 to 45.0 g/kg. Animals were sacrificed 1 to 365 days after VP-VA injection. Tissues were stained and examined by electron microscopy. One to two days after intratracheal injection, alveoli were filled with macrophages. VP-VA and its associated macrophages remained in the lungs 4 to 6 months after the last injection. No VP-VA was observed in the lungs of animals sacrificed one year after the last injection. Following subcutaneous injection, most VP-VA was stored in the spleen. Large macrophages were occasionally observed in the pulmonary interstitial tissue. No evidence of tumors or systemic disease was found during the 1-year observation period. ...
For more complete data on the absorption, distribution, and excretion of 2-pyrrolidone and 1-vinyl- (11 compounds in total), please visit the HSDB record page.

---

Metabolism/Metabolites
...The hydrolysis of N-vinylpyrrolidone (N-VP) was investigated at 37°C and pH 1.2–7.2. ...The major hydrolysis products, accounting for approximately 95% of the hydrolyzed N-VP, were identified as 2-pyrrolidone and acetaldehyde (hydrated form), with acetaldehyde hemihydrate accounting for the remaining 5%.
Preliminary studies have been conducted on the binding capacity of N-VP to plasma or microsomal proteins in vitro. Only up to 12% of N-VP or its metabolites bound to proteins, further supporting the conclusion that N-VP is not metabolized into alkylated substances.

---

Biological Half-Life
The in vivo distribution of N-[14C]-vinyl-2-pyrrolidone following a single intravenous injection in male Sprague-Dawley rats was investigated. The plasma half-life was 1.9 hours.
...The hydrolysis of N-vinylpyrrolidone (N-VP) in the range of 37 °C and pH 1.2–7.2 was studied. ...The hydrolysis rate was inversely proportional to pH. At pH 1.2, the half-life of N-VP in aqueous solution was only about 1.5 minutes; in the pH range of 2.2–2.5, a half-life of 20–40 minutes was observed; at pH 3.5, the half-life was extended to more than 6 hours; and at pH 7.2, N-VP was stable in aqueous solution for at least 24 hours.

Three fasted dogs were administered N-vinylpyrrolidone (N-VP) aqueous solution via nasogastric tube at doses of 5, 10, and 20 mg/kg, respectively, while non-fasted dogs were given a dose of 20 mg/kg (fasted overnight, fed 30 minutes prior to administration). …Plasma elimination followed an exponential pattern, with a half-life between 0.3 and 0.6 hours, independent of dose.
…14C(vinyl)-N-VP aqueous solution was injected intravenously into anesthetized rats. …Blood elimination followed a biphasic pattern, with a slow phase half-life of approximately 1.5–1.9 hours. These half-life values are higher than those calculated in previous oral and other intravenous administration studies.

[1]. Laboratory evaluation of different formulations of Stress Coat? for slime production in goldfish (Carassius auratus) and koi (Cyprinus carpio). PeerJ. 2017 Sep 6;5:e3759.

N-Vinyl-2-pyrrolidone is a type of pyrrolidone compound.
See also: Polyvinylpyrrolidone (note moved to).

C6H9NO

111.1418

9003-39-8

9003-39-8;109412-11-5;25249-54-1

6917

White to off-white solid powder

1.144g/cm3

217.6ºC at 760 mmHg

130ºC

93.9ºC

0.69

0

1

1

8

120

0

O=C1C([H])([H])C([H])([H])C([H])([H])N1C([H])=C([H])[H]

PVP; Polyvidone; Povidone;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

H2O : ≥ 50 mg/mL
DMSO : ~25 mg/mL

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)